Doxifluridine
Furtulon · Antimetabolite (oral 5-FU prodrug)
5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.
Antimetabolite (oral 5-FU prodrug)
Mifurol · HCFU
Antimetabolite (oral 5-FU prodrug) · approved 1981 · 3 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Oral 5-FU prodrug used mainly in Japan; kidney-sparing as a class, better known for leukoencephalopathy than nephrotoxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No established drug-specific renal incidence. Renal risk is class-level (rare fluoropyrimidine TMA/HUS). Carmofur's characteristic serious toxicity is leukoencephalopathy, not nephrotoxicity.Source: Gupta et al., Adv Chronic Kidney Dis 2021 (class-level)
Variable onset, with class-level TMA arising after cumulative exposure.
Distilled from: “Variable; class-level TMA after cumulative exposure.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Thrombotic Microangiopathy strikes: Glomerulus, Vasculature / Endothelium.
Thrombotic Microangiopathy
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
1-Hexylcarbamoyl-5-fluorouracil (HCFU) is a lipophilic oral prodrug that releases 5-fluorouracil, whose active metabolites inhibit thymidylate synthase and incorporate into RNA/DNA to block nucleotide and nucleic-acid synthesis. Its lipophilicity favors sustained 5-FU exposure.
Class-level context for the major non-renal toxicities of the Antimetabolite (oral 5-FU prodrug) class.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Hematologic
Cytopenias, thrombosis, TMA
Pulmonary
Pneumonitis, ILD, effusions, hypertension
3 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 2 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
2 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Carmofur (HCFU) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Furtulon · Antimetabolite (oral 5-FU prodrug)
5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.
UFT · Antimetabolite (oral 5-FU prodrug)
Oral tegafur+uracil; rare fluoropyrimidine-class TMA/HUS (often with mitomycin C), otherwise kidney-sparing.
Rasonque · RAS(ON) multi-selective inhibitor
2026 first RAS(ON) inhibitor (mutant + wild-type RAS) for pretreated metastatic pancreatic cancer; creatinine rose in 24% vs 9% on chemotherapy beside 67% diarrhea, and the label names one renal-limited TMA.
Jakafi · JAK1/2 inhibitor
Tumor lysis in myelofibrosis; renally adjusted.
Dacogen · Hypomethylating agent
Tumor lysis in MDS/AML.
Xeloda · Pyrimidine analog (oral 5-FU)
Diarrhea-driven prerenal AKI; dose-adjust for CrCl.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.